Anterior Uveitis Secondary to Avelumab and Pembrolizumab in a Patient with Metastatic Renal Cell Carcinoma—A Case Report

Anterior Uveitis Secondary to Avelumab and Pembrolizumab in a Patient with Metastatic Renal Cell Carcinoma—A Case Report

We present an unusual case of uveitis secondary to avelumab and pembrolizumab in a 39-year-old Taiwanese male with stage IV clear cell renal cell carcinoma (ccRCC) and lung metastasis, who initially received pembrolizumab as his primary treatment. However, the patient experienced skin and liver immu...

Full description

Bibliographic Details
Main Authors:	Wei-Lun Chu, Kai-Chun Cheng, Pei-Kang Liu, Hung-Chi Lai, Kuo-Jen Chen, Yo-Chen Chang
Format:	Article
Language:	English
Published:	MDPI AG 2024-03-01
Series:	Reports
Subjects:	case report uveitis immune checkpoint inhibitor avelumab pembrolizumab
Online Access:	https://www.mdpi.com/2571-841X/7/1/19

Similar Items

Bilateral anterior uveitis after immunotherapy for malignant melanoma
by: Chia-Jui Chang, et al.
Published: (2018-01-01)

Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab
by: Carmen Navarro-Perea, et al.
Published: (2019-01-01)

Delayed onset anterior uveitis and macular edema after cessation of pembrolizumab
by: Mauranda Men, et al.
Published: (2022-09-01)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
by: Nozomi Hayakawa, et al.
Published: (2023-01-01)

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
by: Ulrich Keilholz, et al.
Published: (2019-01-01)

Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab
by: Wan-Hua Cho, et al.
Published: (2023-01-01)

A case of complete response to avelumab plus axitinib combination therapy for metastatic clear cell renal cell carcinoma in a kidney undergoing dialysis
by: Ei Shiomi, et al.
Published: (2024-03-01)

Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
by: Sandy Tun Min, et al.
Published: (2019-08-01)

Avelumab in metastatic collecting duct carcinoma of the kidney: a case report
by: Nikolaos Pyrgidis, et al.
Published: (2023-06-01)

Relapse of Birdshot Uveitis after Stopping Immunosuppressive Treatment and Starting Immune Checkpoint Inhibitors for Lung Cancer
by: Mohammed A.M. Alsaddi, et al.
Published: (2022-11-01)

Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas
by: Robert Roskoski, Jr.
Published: (2024-05-01)

Trial watch: Immune checkpoint blockers for cancer therapy
by: Claire Vanpouille-Box, et al.
Published: (2017-11-01)

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)
by: Nieves Martinez Chanza, et al.
Published: (2021-12-01)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
by: Tiako Meyo M, et al.
Published: (2022-07-01)

A case of Avelumab response to multiple bone and lymph node metastases of plasmacytoid variant bladder cancer
by: Kazuki Kokura, et al.
Published: (2023-03-01)

Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
by: Bharmal M, et al.
Published: (2019-05-01)

Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination
by: Chiara Masucci, et al.
Published: (2023-06-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
by: Jeffrey M. Conroy, et al.
Published: (2019-01-01)

Switch maintenance therapy for advanced bladder cancer: A paradigm shift in 2020
by: Neal S. Chawla, et al.
Published: (2020-01-01)

Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review
by: Kenta Takahashi, et al.
Published: (2024-03-01)

Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real‐world experience in Israel
by: Itamar Averbuch, et al.
Published: (2023-06-01)

Maintenance avelumab in a patient with metastatic urothelial carcinoma on hemodialysis: A case report
by: Sarah Belay, et al.
Published: (2022-12-01)

Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors
by: Anastasiya A. Glibka, et al.
Published: (2022-10-01)

Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe
by: Kate Fife, et al.
Published: (2021-05-01)

The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
by: B. Ya. Alekseev, et al.
Published: (2021-06-01)

Interstitial nephritis secondary to treatment with pembrolizumab, a rare complication in two patients with lung adenocarcinoma
by: Diana Alexandra Gonçalves Pimenta, et al.
Published: (2022-07-01)

A cost‐utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan
by: Wen‐Cheng Chang, et al.
Published: (2021-12-01)

Early development of pembrolizumab‐induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma
by: Soo Yeon Jang, et al.
Published: (2022-09-01)

Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program
by: Giovanni Grignani, et al.
Published: (2021-02-01)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
by: Stefania Napolitano, et al.
Published: (2022-06-01)

Product review: avelumab, an anti-PD-L1 antibody
by: Julie M. Collins, et al.
Published: (2019-04-01)

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
by: Howard L. Kaufman, et al.
Published: (2018-01-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
by: Jun Kamei, et al.
Published: (2022-05-01)

Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
by: Ioannis Kournoutas, et al.
Published: (2024-02-01)

Hyperprogressive disease after avelumab maintenance therapy in a patient with advanced ureter cancer: A case report
by: Keita Ogasawara, et al.
Published: (2022-11-01)

Molecular Farming of Pembrolizumab and Nivolumab
by: Michael C. Stark, et al.
Published: (2023-06-01)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
by: A.B. Pierre, et al.
Published: (2023-12-01)

Avelumab for the treatment of patients with Merkel cell carcinoma
by: K. V. Orlova, et al.
Published: (2020-07-01)